JAZZ: Jazz Pharmaceuticals plc - Summary | Jitta

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Price
$131.03
Loss Chance
43.5%
5.31JITTA SCORE
48.09%Under Jitta Line
Jitta Ranking
44 / 1,158
681 / 5,058
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (58)
Recent Business Performance (83)
Financial Strength (67)
Return to Shareholders (44)
Competitive Advantage (72)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
CapExVery Low
Interest Coverage RatioGood
SG&A to SalesDecreasing
Revenue and EarningEarning decline from 2019-2022
Operating MarginInconsistent
Debt LevelHigh Long Term Debt
Key Stats
Jitta Score
Jitta Line
5.31
48.09%
1.97
169.24%
2.00
168.74%
Pharmaceuticals
2.62
91.57%
6.63
34.28%
4.26
83.16%
COMPANY DESCRIPTION
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company’s lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.